Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20580329 | 0.86 | ALDH1A1 (0.46) | ALDH1A1CNR1CNR2KDM4ESOAT1 | |
| SCHEMBL28312770 | 0.85 | HTT (0.48) | ALDH1A1 | |
| SCHEMBL6261092 | 0.85 | ALDH1A1 (0.58) | ALDH1A1CNR1CNR2 | |
| SCHEMBL12474184 | 0.85 | ALDH1A1 (0.58) | ALDH1A1CNR1CNR2 | |
| SCHEMBL24555968 | 0.83 | KDM4E (0.53) | ALDH1A1CNR1KDM4ESOAT1 | |
| SCHEMBL18546028 | 0.83 | ALDH1A1 (0.56) | ALDH1A1CNR1CNR2 | |
| SCHEMBL16510791 | 0.83 | ALDH1A1 (0.56) | ALDH1A1CNR1CNR2 | |
| SCHEMBL15054267 | 0.83 | ALDH1A1 (0.56) | ALDH1A1CNR1CNR2 | |
| SCHEMBL18546023 | 0.83 | ALDH1A1 (0.56) | ALDH1A1CNR1CNR2 | |
| SCHEMBL18546025 | 0.83 | ALDH1A1 (0.56) | ALDH1A1CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12636252-B2 | Process of preparing mRNA-loaded lipid nano particles | TRANSLATE BIO, INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-20260124291-A1 | RHINOVIRUS MRNA VACCINE | SANOFI PASTEUR (FR) | 2026-05-07 | — | — | US | disclosed |
| US-12605399-B2 | Compositions for CFTR MRNA therapy | TRANSLATE BIO, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-12594245-B2 | Dry powder formulations for messenger RNA | TRANSLATE BIO, INC. (US) | 2026-04-07 | — | — | US | disclosed |
| US-12576030-B2 | Compositions for delivery of codon-optimized mRNA | TRANSLATE BIO, INC. (US) | 2026-03-17 | — | — | US | disclosed |
| US-12569572-B2 | Messenger RNA therapy for the treatment of Friedreich's ataxia | TRANSLATE BIO, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-12564645-B2 | Methods for treatment of methylmalonic acidemia | TRANSLATE BIO, INC. (US) | 2026-03-03 | — | — | US | disclosed |
| EP-4698156-A1 | RECONSTITUTABLE DRY POWDER FORMULATIONS AND METHODS OF USE THEREOF | Sanofi Pasteur Inc. (US) | 2026-02-25 | — | — | EP | disclosed |
| US-12545636-B2 | Acyclic lipids and methods of use thereof | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2026-02-10 | — | — | US | disclosed |
| EP-4467653-B1 | IMPROVED MRNA-LOADED LIPID NANOPARTICLES AND PROCESSES OF MAKING THE SAME | TRANSLATE BIO INC (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20190298658-A1 | Polynucleotides Encoding Cystic Fibrosis Transmembrane Conductance Regulator for the Treatment of Cystic Fibrosis | MODERNATX, INC. (US) | 2019-10-03 | — | — | US | disclosed |
| US-20190275170-A1 | POLYNUCLEOTIDES ENCODING JAGGED1 FOR THE TREATMENT OF ALAGILLE SYNDROME | MODERNATX, INC. (US) | 2019-09-12 | — | — | US | disclosed |
| US-20190117798-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | MODERNATX, INC. (US) | 2019-04-25 | — | — | US | disclosed |
| EP-3458107-A1 | POLYNUCLEOTIDES ENCODING JAGGED1 FOR THE TREATMENT OF ALAGILLE SYNDROME | ModernaTX, Inc. (US) | 2019-03-27 | — | — | EP | disclosed |
| EP-3458108-A1 | POLYNUCLEOTIDES ENCODING CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FOR THE TREATMENT OF CYSTIC FIBROSIS | ModernaTX, Inc. (US) | 2019-03-27 | — | — | EP | disclosed |
| US-10207010-B2 | Compositions and methods for delivery of agents | MODERNATX, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20180147298-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | MODERNATX, INC. (US) | 2018-05-31 | — | — | US | disclosed |
| US-20180028664-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | MODERNATX, INC. (US) | 2018-02-01 | — | — | US | disclosed |
| WO-2017201347-A1 | POLYNUCLEOTIDES ENCODING CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FOR THE TREATMENT OF CYSTIC FIBROSIS | MODERNATX, INC. (US) | 2017-11-23 | — | — | WO | disclosed |
| WO-2017201342-A1 | POLYNUCLEOTIDES ENCODING JAGGED1 FOR THE TREATMENT OF ALAGILLE SYNDROME | MODERNATX, INC. (US) | 2017-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260124291-A1 | RHINOVIRUS MRNA VACCINE | RPP30, RNGTT, EIF4A3 | ALDH1A1 4719/4885CNR1 3817/4885CNR2 3793/4885 |
| US-12569572-B2 | Messenger RNA therapy for the treatment of Friedreich's ataxia | SMN1; SMN2, CDR2, ATXN2 | ALDH1A1 3706/4885CNR1 4319/4885CNR2 3793/4885 |
| US-20190117798-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | HDLBP, APOB, TSG101 | ALDH1A1 3952/4885CNR1 3925/4885CNR2 4222/4885 |
| US-12636252-B2 | Process of preparing mRNA-loaded lipid nano particles | RNMT, SOAT2, METTL16 | ALDH1A1 4136/4885CNR1 4356/4885CNR2 4140/4885 |
| US-12576030-B2 | Compositions for delivery of codon-optimized mRNA | DYNLL1, STARD3, DYNC1I2 | ALDH1A1 2463/4885CNR1 3403/4885CNR2 4550/4885 |
| US-10207010-B2 | Compositions and methods for delivery of agents | HDLBP, APOB, TSG101 | ALDH1A1 3952/4885CNR1 3925/4885CNR2 4222/4885 |
| US-12545636-B2 | Acyclic lipids and methods of use thereof | PLTP, LNPEP, PCTP | ALDH1A1 4885/4885CNR1 3071/4885CNR2 2980/4885 |
| US-12564645-B2 | Methods for treatment of methylmalonic acidemia | MMAB, METTL16, COASY | ALDH1A1 3461/4885CNR1 4626/4885CNR2 4588/4885 |
| US-12594245-B2 | Dry powder formulations for messenger RNA | METTL16, RBM25, RNMT | ALDH1A1 4188/4885CNR1 2305/4885CNR2 885/4885 |
| US-20180147298-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | HDLBP, APOB, TSG101 | ALDH1A1 3952/4885CNR1 3925/4885CNR2 4222/4885 |
| US-20190298658-A1 | Polynucleotides Encoding Cystic Fibrosis Transmembrane Conductance Regulator for the Treatment of Cystic Fibrosis | CFTR, SLC47A1, TMEM205 | ALDH1A1 3662/4885CNR1 1589/4885CNR2 2206/4885 |
| US-20180028664-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | HDLBP, APOB, TSG101 | ALDH1A1 3952/4885CNR1 3925/4885CNR2 4222/4885 |
| US-12605399-B2 | Compositions for CFTR MRNA therapy | CFTR, UPF1, CLCN2 | ALDH1A1 4607/4885CNR1 2823/4885CNR2 2688/4885 |
| US-20190275170-A1 | POLYNUCLEOTIDES ENCODING JAGGED1 FOR THE TREATMENT OF ALAGILLE SYNDROME | AARS1, IARS1, NOTCH1 | ALDH1A1 1611/4885CNR1 3090/4885CNR2 3933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.